|
 |
VisudyneThis page contains recent news articles, when available, and an overview of Visudyne but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.QOI will take on the sales and marketing of Visudyne(R) in the US from Novartis Pharma AG ("Novartis") effective January 1, 2010 as a result of the Amended ... TMCnet QLT Inc. Announces Establishment Of US Subsidiary - Quick Facts - Dec 22, 2009 TO: News ) announced the establishment of its US subsidiary, QLT Ophthalmics Inc. QLT Ophthalmics will take on the sales and marketing of Visudyne in the US ... RTT News QLT begins phase 1b trial of Leber's congenital amaurosis treatment, launches ... - Dec 23, 2009 Novartis will retain all distribution, sales and marketing rights for Visudyne outside the US "This is an important milestone in the history of the company, ... OSN SuperSite QLT Acquires Early-Stage Ophthalmic Asset for US$7.5 Million - Dec 30, 2009 We are focused on our commercial product Visudyne(R) for the treatment of wet-AMD, and the development of drugs to be delivered in our proprietary punctal ... CNNMoney.com (press release) Combined triamcinolone acetonide-PDT may reduce number of re-treatments - Dec 10, 2009 The 2-year, randomized, multicenter, sham-controlled trial included 100 patients older than 50 years assigned to undergo PDT with Visudyne (verteporfin, ... OSN SuperSite The Canadian Press Business News Budget for Tuesday, Dec. 22, 2009 - Dec 23, 2009 VANCOUVER _ QLT Inc. (TSX:QLT) forms new subsidiary, called QLT Ophthalmics, Inc., to take on the US sales and marketing of the Visudyne treatment for ... TMCnet Novartis set to sustain its leading global position in oncology with portfolio ... - Dec 12, 2009 Another study, EVEREST, showed the combination of Visudyne and Lucentis improved eyesight and significantly reduced vessel abnormalities in patients with ... PR-USA.net (press release) QLT Inc.在美国设立销售部门 - Dec 22, 2009 ...æ ¹æ?®è¿™ä»½å??è®®,QLT 将获得针对Visudyne 专利的独家æ?ƒåˆ©,能在美国销售与推广Visudyne。诺å?Žä»?将负责Visudyne 在美国外所有国家的分销ã€?销售和è?¥é”€ã€‚ ... 证券之星 QLT Gets Exclusive US Rights To Visudyne >QLTI - Oct 19, 2009 QLT Inc. (QLTI) will soon have exclusive US sales and marketing rights to Visudyne after reaching a restructured agreement with Novartis Pharma AG (NVG), ... Wall Street Journal QLT Q3 2009 Earnings Call Transcript - Oct 27, 2009 The risk of future sales of Visudyne or Elegard may be less than expected. Uncertainties relating to costs and success of R&D, commercialization of products ... Seeking Alpha (blog) QLT restructures Visudyne(R) agreement - Oct 19, 2009 QLT will continue to manufacture Visudyne and will supply the product at a pre-specified price exclusively to Novartis for ex-US distribution. ... Reuters QLT, Novartis restructure Visudyne deal; Teva launches Copaxone patent battle ... - Oct 19, 2009 Canadian eye-care company QLT said it restructured its pact with Novartis, giving it exclusive rights to sell anti-blindness treatment Visudyne in the ... FiercePharma QLT announces Toronto Stock Exchange approval of share repurchase program - Oct 28, 2009 We utilize two unique technology platforms, photodynamic therapy (used with the Visudyne product) and punctal plugs, which are currently under development ... Reuters QLT Inc. Reports Operating Results (10-Q) - Nov 6, 2009 Under the Amended PDT Agreement, effective January 1, 2010, we will, among other things, receive exclusive US rights to the Visudyne® patents to sell and ... GuruFocus.com QLT announces third quarter results for 2009 - Oct 27, 2009 Worldwide Product Sales Worldwide Visudyne(R) sales for the third quarter were $23.5 million, a decrease of 31.1% from sales in the third quarter of 2008. ... Reuters Materials Stocks Lead TSX To Four-Week High - Canadian Commentary - Oct 19, 2009 ...under which it will receive exclusive US rights to the Visudyne patents to sell and market Visudyne in the US the stock lost 2.7% on the day. ... RTT News QLT Announces Share Repurchase Program - Oct 27, 2009 We utilize two unique technology platforms, photodynamic therapy (used with the Visudyne product) and punctal plugs, which are currently under development ... Reuters NEW YORK, Oct 19 (Reuters) - Some US stocks to watch on Monday: - Oct 19, 2009 The company restructured its pact with Novartis Pharma AG, giving it exclusive rights to sell the anti-blindness treatment Visudyne in the United States. ... Forbes QLT Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new ... - Nov 13, 2009 QLT has two commercial products, Visudyne and Eligard. Visudyne utilizes photodynamic therapy (PDT), to treat the eye disease known as wet age related ... PR-inside.com (press release) AAO: Photodynamic Therapy No Help in Treating Macular Degeneration - Oct 29, 2009 Visual acuity after 12 months of verteporfin (Visudyne) plus ranibizumab (Lucentis) was statistically noninferior to ranibizumab monotherapy (P=0.0051), ... MedPage Today New Report Just Published Ophthalmological Therapeutics: A Promising and ... - Oct 23, 2009 Sales and Revenue Figures for Visudyne and US Sales Share, 2000-2006 Table 5.1. Selected Alcon IP Documents Directed at Glaucoma and Published in 2006 Table ... Live-PR.com (Pressemitteilung) Early Movers: Pump Up the Volume - Oct 19, 2009 ...it restructured an agreement with Novartis (NVS Quote) to receive exclusive US rights to sell and market the anti-blindness treatment Visudyne in the US ... TheStreet.com CA-BUSINESS Summary - Oct 19, 2009 The company, which shares revenue from Visudyne sales with global marketing partner Novartis, said it will also have rights to all end-user revenue derived ... ReportonBusiness.com Pay Attention To QLT - Oct 29, 2009 Revenues for QLT now come from a single product, Visudyne, which is marketed by drug giant Novartis (NYSE: NVS). Its second product, Eligard, ... Investopedia CA-BUSINESS Summary - Oct 19, 2009 The company, which shares revenue from Visudyne sales with global marketing partner Novartis, said it will also have rights to all end-user revenue derived ... ReportonBusiness.com CANADA STOCKS-TSX could follow commodities to higher open - Oct 19, 2009 VX: Quote, Profile, Research), giving QLT the exclusive rights to sell anti-blindness treatment Visudyne in the United States. ... Reuters India QLTé‡?整与Novartis Pharma AG之间å??è®® - Oct 19, 2009 ...(QLTI) 3.98 : QLT宣布，他们é‡?整与NovartIS Pharma AG之间å??议，将简化å?Œæ–¹å…³ç³»ï¼Œä»Ž2010å¹´1月1日起，QLT独家å?–å¾—Visudyne专利æ?ƒçš„美国拳利，将在美国销售与 ... 凤凰网 QLT says Visudyne sales fell in fourth quarter - Jan 17, 2008 TORONTO, Jan 17 (Reuters) - Sales of QLT Inc's (QLT.TO) (QLTI.O) anti-blindness treatment Visudyne dropped more than 40 percent in the fourth quarter, ... Reuters … CHMP to recommend deleting 'occult' indication of Visudyne drug in... - Apr 25, 2007 Visudyne is currently approved for the treatment of patients with both 'classic' and ... Full-year sales of Visudyne totalled 358.8 mln usd last year, ... Forbes QLT's global Visudyne sales drop 43 pct in 1st qtr - Apr 23, 2007 ...(Adds details, analyst comments; changes dateline from New York. Figures in US dollars unless noted). TORONTO, April 23 (Reuters) - Sales of QLT Inc.'s (QLT ... Reuters Downgrades QLT On Genentech Data - Jul 18, 2005 Even a study presented at the American Society of Retinal specialists (ASRS) in Montreal that showed Lucentis worked will in combination with Visudyne may ... Forbes QLT posts loss; sales of eye drug Visudyne slump - Feb 21, 2008 TORONTO (Reuters) - QLT Inc (QLT.TO: Quote) reported a fourth-quarter loss on Thursday, hurt by slumping sales of its drug Visudyne to fight macular ... Reuters Canada QLT hit by weak Visudyne sales, pain seen lingering - Feb 22, 2007 By Scott Anderson. TORONTO, Feb 22 (Reuters) - QLT Inc. (QLT.TO) reported a fourth-quarter loss on Thursday, hurt by a charge related to litigation at its ... Reuters QLT narrows quarterly loss but Visudyne sales slump - Jul 29, 2008 TORONTO (Reuters) - QLT Inc said on Tuesday that it narrowed its second-quarter loss considerably compared with the second quarter of 2007 when its results ... Reuters Canada QLT drops to loss on legal charges, Visudyne - Jul 26, 2007 TORONTO, July 26 (Reuters) - QLT Inc. (QLT.TO) reported a huge second-quarter loss on Thursday, primarily due to costs surrounding a July court ruling that ... Reuters QLT lowers Visudyne's 2007 outlook as sales sag - Oct 18, 2007 O) unveiled a 2007 sales outlook for its Visudyne eye treatment on Thursday that was ... Although QLT has not provided a recent sales outlook for Visudyne, ... Reuters QLT says Visudyne sales slip 31.5 percent - Jul 17, 2008 TORONTO, July 17 (Reuters) - Sales of QLT Inc's (QLT.TO) (QLTI.O) anti-blindness treatment Visudyne dropped more than 30 percent in the second quarter, ... Reuters Visudyne Q1 sales down 13.7%, QLT reports - Apr 24, 2006 QLT Inc. reported Monday that global sales of the eye drug Visudyne, its main source of revenue, dropped by 13.7 per cent to $106.8 million US in the first ... CBC.ca QLT cuts revenue outlook after Visudyne sales drop - Oct 19, 2006 Pharmaceutical company QLT Inc. reduced its annual sales outlook for the eye treatment Visudyne after a partner reported lower third-quarter sales of the ... CBC.ca QLT posts Q1 loss on lower Visudyne sales - Apr 25, 2008 QLT Inc. has reported a worse-than-expected first-quarter net loss of $10.5 million US as sales of its key Visudyne eye drug faded 40 per cent from a year ... CBC.ca QLT's fourth-quarter Visudyne sales fall 29 pct - Jan 18, 2007 TORONTO, Jan 18 (Reuters) - Sales of QLT Inc.'s (QLT.TO) (QLTI.O) anti-blindness treatment Visudyne fell 29 percent in the fourth quarter, the company said ... Reuters QLT's Visudyne sales drop 30 percent - Oct 20, 2008 TORONTO, Oct 20 (Reuters) - Sales of QLT Inc's (QLT.TO) (QLTI.O) anti-blindness treatment Visudyne dropped 30 percent in the third quarter, the company said ... Reuters QLT's Visudyne sales drop 38 pct in second quarter - Jul 17, 2007 TORONTO, July 17 (Reuters) - Sales of QLT Inc.'s (QLT.TO) (QLTI.O) anti-blindness treatment Visudyne slumped 38 percent in the second quarter, ... Reuters Genentech Phase I/II study shows ophthalmology drug Lucentis improves... - May 31, 2005 Around 90 pct of patients 'maintained or improved' vision when treated with the combination of Lucentis and Visudyne compared to approximately 68 pct of ... Forbes Visudyne sales slip 13% as competition grows - Jan 20, 2006 Sales of Vancouver-based QLT Inc.'s eye drug Visudyne slipped 13 per cent in the fourth quarter, compared with a year ago, amid growing competition. ... Pay-Per-View - Toronto Star - ProQuest Archiver QLT Falls on Eye Treatment Study - Sep 21, 2005 Trials of Vacouver-based QLT's drug Visudyne plus photodynamic therapy failed ... Visudyne was approved in 2000 for patients with "classical" AMD lesions. ... TheStreet.com - TheStreet.com (subscription) Maker of Visudyne cuts 80 jobs, sales forecast - Oct 27, 2006 QLT Inc. said it fell to a loss in the third quarter. It also lowered its guidance and cut 80 jobs yesterday after reporting that sales of its key drug ... Pay-Per-View - Toronto Star - ProQuest Archiver QLT Eyes Big Job Cuts | Biotech/Pharmaceuticals News | Print Financial... - Dec 8, 2005 Visudyne is a treatment for a condition that can lead to blindness, ... QLT said that while it expects Visudyne to remain an important option for patients, ... TheStreet.com - TheStreet.com (subscription) QLT says Visudyne sales drop 40.4 pct - Apr 21, 2008 TORONTO, April 21 (Reuters) - Sales of QLT Inc's (QLT.TO) (QLTI.O) anti-blindness treatment Visudyne dropped more than 40 percent in the first-quarter, ... Reuters Visudyne maker battered by competitor's test results - May 25, 2005 Lucentis, a treatment for age-related macular degeneration, could become the second big competitor for Visudyne, Vancouver-based QLT's main source of ... Pay-Per-View - Toronto Star - ProQuest Archiver Drug shares eke out gains, biotechs close lower - Jul 17, 2006 QLT Inc. (NASDAQ:QLTI) shares, meanwhile, lost 4.5% after Novartis said global second-quarter sales of Visudyne fell 26.1% from the same period last year, ... MarketWatch QLT reports a slim profit, to cut R&D costs - Oct 25, 2007 O) said on Thursday it expects to record a fourth-quarter charge as another weak performance from its key Visudyne anti-blindness treatment forces it to cut ... Reuters Genentech's Lucentis Cleared - Jun 30, 2006 When Lucentis becomes available, Visudyne won't be its only competition. Another option for treating AMD is Macugen, a drug sold by OSI Pharmaceuticals ... TheStreet.com - TheStreet.com (subscription) Drug maker QLT mulls sale of all, part of assets - Nov 28, 2007 The Canadian pharmaceutical company, known for its Visudyne anti-blindness ... Although QLT is known for its Visudyne anti-blindness treatment, analysts see ... Reuters QLT to lay off 46% of staff and reduces guidance for Visudyne - Dec 9, 2005 By DON LONG. QLT (Vancouver, British Columbia) - originally founded and focused on photodynamic therapy, a drug for treatment of macular degeneration ... Free with registration - Medical Device Week - AccessMyLibrary.com 2006 Visudyne Sales Guidance - Feb 22, 2006 Based on recent events and current trends in Visudyne sales, QLT is projecting that Visudyne sales will range from $370 million to $400 million in 2006. ... Free with registration - PR Newswire - AccessMyLibrary.com BC biotech companies skyrocket - Mar 18, 2008 The company plans to concentrate on its lead product Visudyne, a combination therapy for age-related blindness, and on punctual plugs, a delivery system for ... Canada.com QLT settles 2001 lawsuits over Visudyne - Mar 5, 2007 VANCOUVER – QLT Inc. (TSX: QLT) has settled most of its patent lawsuits with Massachusetts Eye and Ear Infirmary related to a 2001 dispute over its Visudyne ... Toronto Star Genentech's Peer Premium Seen Well Justified - Jan 17, 2006 ...compared with a loss of 9.5 letters for patients treated with Visudyne, a drug currently marketed by Novartis (nyse: NVS - news - people ). ... Forbes Lucentis beats Visudyne in trial - Nov 7, 2005 In a head-to-head trial against Novartis' own drug Visudyne, Novartis and partner Genentech's experimental drug Lucentis was found to be more effective in ... FierceBiotech QLT announces interim results of radical study evaluating Visudyne … - Dec 16, 2008 ..."Determining if Visudyne therapy in combination with Lucentis with or ... Based on the six-month data review for Visudyne combination therapy and the DSMC's ... International Business Times Drug firm's CEO steps down, VP named acting chief - Sep 27, 2005 Butchofsky helped launch and commercialize Visudyne, the company's ... Visudyne has been approved in the U.S. for classic age-related macular degeneration. ... Pay-Per-View - Toronto Star - ProQuest Archiver Visudyne IV : User Ratings covering uses, effectiveness, interactions... - Jul 21, 2008 I am 33 and I had my 5th PDT with Visudyne and I also had an Avastin shot immediately after. I completely lost my sight for 5 minutes which was scary but I ... WebMD Mass. Eye and Ear, Mass. General win court ruling - Jul 11, 2007 A federal judge in Boston adopted a jury decision reached in November that QLT should pay royalties of about 3 percent on net sales worldwide of Visudyne, ... Boston Globe QLT found liable for Visudyne royalties. - Nov 7, 2006 NEW YORK (AFX) - QLT Inc., a Canadian maker of biotech therapies to treat eye diseases, said late Monday that a federal jury ruled against it in a lawsuit ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com GENENTECH TOUTS VISION THERAPY RESULTS - Nov 8, 2005 Genentech's Lucentis was more effective than QLT's therapy Visudyne at preserving sight in patients with an aggressive form of age-related macular ... $2.95 - San Jose Mercury News - NewsBank Positive results from Visudyne(R) combination therapy study reported... - Mar 31, 2008 QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that results from an investigator-sponsored Phase II study, in patients with subfoveal choroidal ... Lifescience-online Event Brief of Q1 2006 QLT Inc. Earnings Conference Call - Part 1. - Apr 27, 2006 The Co. continued to gain more visibility with Visudyne and usage patterns ... Continues to believe that Visudyne will remain an important treatment option ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com QLT tumbles on lower Visudyne view, restructuring plans. - Dec 8, 2005 NEW YORK (MarketWatch) -- Shares of QLT Inc. fell almost 9% to $6.35 after the company announced a restructuring plan and lowered its 2005 outlook for sales ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com QLT cuts sales outlook for key drug Visudyne - Oct 19, 2007 QLT Inc dropped the 2007 sales outlook for its Visudyne eye treatment to well below analysts' expectations yesterday, following disappointing third-quarter ... Toronto Star Visudyne sales slump, share buyback planned - Jul 28, 2006 QLT Inc., the Vancouver-based drug company, posted a $7.5 million (U.S.) profit, or 8 cents a share, for the period ended June 30. ... Pay-Per-View - Toronto Star - ProQuest Archiver Event Brief of Q4 2004 QLT Inc. Earnings and Conference Call - Final. - Feb 23, 2005 QLTI announced Visudyne 4Q04 sales of $124m and $448m for the full year. ... Medicare's decision to reimburse certain patients for Visudyne was a key event. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Press Release: QLT announces 2 year results of Visudyne(R) in Occult... - Sep 20, 2005 QLT announces 2 year results of Visudyne(R) in Occult (VIO) trial. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … Release: QLT announces second quarter 2008 Visudyne(R) sales. - PR... - Jul 17, 2008 QLT announces second quarter 2008 Visudyne(R) sales. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: QLT announces Visudyne(R) sales for third quarter of … - Oct 19, 2006 QLT announces Visudyne(R) sales for third quarter of 2006 and updates annual sales guidance. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Macular degeneration drug listed on PBS - Jun 6, 2007 The listings of Lucentis and Visudyne will add around $630 million to PBS and RPBS over the next five years. Around 129000 patients have age related macular ... 6minutes Q2 2006 QLT Inc. Earnings Conference Call - Final. - Jul 27, 2006 Forward-looking statements include the Company's 2006 Visudyne and Eligard sales ... However, we expect Visudyne will find its place and remain an important ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com … announces Visudyne(R) sales for third quarter and provides Visudyne... - Oct 18, 2007 QLT announces Visudyne(R) sales for third quarter and provides Visudyne sales guidance for 2007. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: QLT announces Visudyne(R) sales for fourth quarter and... - Jan 17, 2008 QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2007. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research QLT announces 2 year results of Visudyne(R) in Occult (VIO) trial. - Sep 20, 2005 VANCOUVER, Sept. 20 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that preliminary analysis of the intent to treat population ... $4.95 - PR Newswire - ECNext … Release: QLT announces first quarter 2007 Visudyne(R) sales. - PR ... - Apr 23, 2007 QLT announces first quarter 2007 Visudyne(R) sales. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Q3 2006 QLT Inc. Earnings Conference Call - Part 1. - Oct 2, 2006 We are dependent on third parties to commercialize Visudyne and other factors described in ... We continue to measure declines in Visudyne monotherapy, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Arkansas Regulations - 242.150 Verteporfin (Visudyne) - Apr 2, 2008 242.150 Verteporfin (Visudyne) 5-1-07 A. Medicaid reimburses outpatient hospitals for Verteporfin (Visudyne), HCPCS procedure code J3396, ... Pay-Per-View - Arkansas Regulations - Loislaw Event Brief of QLT Inc. Strategic Update - Part 2. - Dec 8, 2005 The second is looking at Visudyne, four patents listed in the orange book that ... Would be looking into ways of using Visudyne in an efficient way but in ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com 3 Canadian scientists named for Herzberg award - Feb 7, 2007 ...be increased to $1 million over the next five years. Last year's winner was David Dolphin, the lead creator of Visudyne, a widely used anti-blindness drug. CBC.ca Photodynamic therapy for age-related macular degeneration - Aug 13, 2007 In photodynamic therapy, a light-sensitive medicine called verteporfin (Visudyne) is injected into the bloodstream. The medicine collects in the abnormal ... WebMD … million operating loss, 40.4% decline in worldwide Visudyne sales... - May 2, 2008 First-quarter Visudyne sales in the United States totaled $9.3 million, ... QLT attributed the decline in Visudyne sales to the approval and reimbursement ... OSN SuperSite Press Release: QLT announces Visudyne(R) sales for fourth quarter and... - Jan 18, 2007 QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2006. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Visudyne sales continue falling during second quarter - Jul 26, 2007 VANCOUVER, British Columbia — Worldwide sales of Visudyne totaled $59.3 million during the second quarter, a 37.8% decrease compared with sales for the ... OSN SuperSite Press Release: QLT announces Visudyne(R) sales for third quarter of … - Oct 18, 2005 QLT announces Visudyne(R) sales for third quarter of 2005. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Visudyne sales drop hammers QLT's first-quarter revenue - Apr 28, 2008 Vancouver-based QLT Inc.'s (TSX:QLT) first-quarter bottom line has been hit hard by plunging sales of Visudyne, one of its leading products. ... Business in Vancouver … Release: QLT announces third quarter 2008 Visudyne(R) sales. - PR ... - Oct 20, 2008 QLT announces third quarter 2008 Visudyne(R) sales. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Positive results from Visudyne(R) combination therapy ... - Mar 28, 2008 Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: QLT announces Visudyne(R) sales for fourth quarter and... - Jan 19, 2006 QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2005. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Visudyne Access Network launched.(product development)(Novartis … - Mar 21, 2005 Novartis Ophthalmics announced that the Visudyne Access Network (VAN) is now available nationwide to retina specialists and their patients with age-related ... Free with registration - Drug Topics - AccessMyLibrary.com Press Release: QLT announces Visudyne(R) sales for fourth quarter and... - Jan 20, 2005 QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2004. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research QLT announces Visudyne(R) sales for fourth quarter and fiscal year... - Jan 20, 2005 QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global Visudyne(R) (verteporfin) sales of approximately US$124 ... $4.95 - PR Newswire - ECNext … Release: QLT announces first quarter 2008 Visudyne(R) sales. - PR ... - Apr 21, 2008 QLT announces first quarter 2008 Visudyne(R) sales. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Eying Profits in Eye Sight - Jan 3, 2005 The only other FDA-approved treatment is market leader Visudyne, ... Injected into the arm, Visudyne is activated by shining a cold laser into the eye which ... fool.com QLT announces Visudyne(R) sales for third quarter of 2005. - Oct 18, 2005 VANCOUVER, Oct. 18 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global ... $4.95 - PR Newswire - ECNext Evizon-Visudyne combo well-tolerated for AMD - Jul 19, 2005 MONTREAL – Squalamine used in conjunction with verteporfin photodynamic therapy “appears to be safe and well-tolerated,â€? said Thomas A. Ciulla, MD. ... OSN SuperSite Genaera reaches target enrolment in two Phase II studies for Squalamin... - Feb 15, 2005 Specifically, this study will evaluate the safety and effects of systemically administered squalamine before and after photodynamic therapy with Visudyne. ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com … of Massachusetts Eye and Ear Infirmary in Visudyne Case. | Article... - Nov 7, 2006 Jury Finds in Favor of Massachusetts Eye and Ear Infirmary in Visudyne Case. ... find AScribe Medicine News Service articles. Pay-Per-View - AScribe Medicine News Service - HighBeam Research Event Brief of Q3 2005 QLT Inc. Earnings Conference Call - Part 1. - Oct 2, 2005 Visudyne sales for 3Q05 were roughly in line with internal forecast. 1. ... Visudyne guidance is $500-530m in sales for 2005, a 12-18% growth rate in sixth ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … Release: QLT announces 2005 results and Visudyne sales guidance... - Feb 22, 2006 QLT announces 2005 results and Visudyne sales guidance for 2006. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: QLT announces Visudyne(R) sales for second quarter of ... - Jul 14, 2005 VANCOUVER, July 14 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q2 2006 QLT Inc. Earnings Conference Call - Part 1. - Jul 27, 2006 ...s announced intention to focus on ocular and its confidence in Visudyne, ... Visudyne: 1. The Co. believes that one of the main reasons the Co. has ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com NSERC: UBC Professor and Lead Creator of Key Ophthalmic Drug Wins … - Mar 20, 2006 The creator of Visudyne TM , one of the world's most successful ophthalmic products, ... Visudyne has been used to treat more than 500000 people since 2000. ... ccnmatthews.com QLT Announces 2006 Results. - Feb 22, 2007 As previously announced, Visudyne(R) sales for the fourth quarter were $76.5 ... Worldwide Visudyne sales were $353.8 million for the full year 2006, ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: QLT announces Visudyne(R) sales for first quarter of … - Apr 21, 2005 QLT announces Visudyne(R) sales for first quarter of 2005. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: QLT Announces Q3 Results and Provides Guidance … - Oct 25, 2007 Profitability of Visudyne is down in the third quarter, however, currently expected to improve ... Article: QLT announces 2005 results and Visudyne sales . ... Pay-Per-View - PR Newswire - HighBeam Research Business & Finance; Visudyne sales for fourth quarter and fiscal year... - Feb 14, 2005 2005 FEB 14 - (NewsRx.com & NewsRx.net) -- QLT Inc. (NASDAQ:QLTI; TSX:QLT) reported that its alliance partner, Novartis, announced global Visudyne ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Lucentis Stalls Blood Vessel Growth in Macular Degeneration - Oct 4, 2006 Patients were randomly assigned in a 1:1:1 ratio to receive monthly intravitreal injections of Lucentis (0.3 mg or 0.5 mg) or sham Visudyne therapy or ... MedPage Today Q2 2005 QLT Inc. Earnings Conference Call - Final. - Jul 28, 2005 Respectable performance in the United States for Novartis in Visudyne, close to 50 million in sales, down a little bit from Q2 last year and, as I said, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Sharks Don't Go Blind - Jan 5, 2005 QLT's Visudyne uses a cold laser to seal off the leaking blood vessels and it's being tested in conjunction with squalamine as a more complete treatment for ... fool.com CHMP recommends revoking approval of Visudyne for CNV. - Apr 30, 2007 CHMP recommends revoking approval of Visudyne for CNV. Canadian biopharmaceutical firm QLT says that the European Medicnies Agency's Committee for Medicinal ... $9.94 - Pharma Marketletter - Alacra Store Business & Finance; Visudyne sales for fourth quarter and fiscal year... - Feb 15, 2005 2005 FEB 15 - (NewsRx.com & NewsRx.net) -- QLT Inc. (NASDAQ:QLTI; TSX:QLT) reported that its alliance partner, Novartis, announced global Visudyne ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones QLT announces partial result in Eligard(R) patent litigation. - Dec 14, 2005 ...photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R). ... Inc. Visudyne is a registered trademark of Novartis AG. ... Free with registration - PR Newswire - AccessMyLibrary.com Genaera Corp announces positive preliminary data for Evizon in... - Feb 25, 2005 MSI-1256F-208 is a Phase II trial designed to evaluate the effects of three different doses of Evizon with initial concomitant Visudyne treatment in 45 ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Press Release: QLT announces Q1 results for 2006 and provides R&D … - Apr 27, 2006 Visudyne(R) worldwide sales for the first quarter were $106.8 million, ... Visudyne sales in the U.S. were $30.5 million, down 40.6% over last year. ... Pay-Per-View - PR Newswire - HighBeam Research QLT's Sagging Sales - Jan 22, 2007 QLT is best known for its macular degeneration treatment, Visudyne, ... Worldwide sales of Visudyne for the quarter came in at $77 million, down 29% from ... fool.com … II Data Showing EVIZON(TM) With Visudyne(R) Demonstrate Safety and... - Oct 11, 2005 ...primary goal of demonstrating safety when dosed concomitantly with photodynamic therapy with Visudyne(R) (PDT) (QLT Incorporated, Vancouver, Canada). ... $4.95 - PR Newswire - ECNext QLT announces Q3 results for 2006, updates guidance, and implements … - Oct 26, 2006 Visudyne(R) worldwide sales for the third quarter were $75.1 million, a decrease of 39.3% ... Visudyne sales in the US for the quarter were $11.0 million, ... Free with registration - PR Newswire - AccessMyLibrary.com Event Brief of Q3 2006 QLT Inc. Earnings Conference Call - Final. - Oct 26, 2006 QLTI continues to measure declines in Visudyne monotherapy, ... Expects that these declines will be offset by increases in Visudyne and the anti-VEGF ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com QLT Eats Itself - Jun 8, 2007 ...(NYSE: DNA) rival macular degeneration treatment, Lucentis, QLT has been under pressure as sales of its top compound Visudyne have shrunk precipitously. ... fool.com QLT Gets Reformulated - Aug 31, 2007 With sales of its age-related macular degeneration treatment, Visudyne, in the dumps, it's impossible to understate just how important Eligard is to QLT. ... fool.com Clear vision for Macugen: the marketers of Macugen, the second drug... - Mar 1, 2005 Visudyne, which is marketed by Novartis Ophthalmics and QLT Inc., ... Visudyne, composed of verteportin, is taken about three times a year. ... Pay-Per-View - Med Ad News - Factiva, from Dow Jones |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |